LTS

LTS develops and manufactures drug delivery systems for pharma partners, with a focus on transdermal therapeutic systems (TTS), oral thin films (OTFs), micro-array patches (MAPs), wearable injectors, nasal, and sterile dosage forms. Its systems are applied in more than 40 marketed products.

Associated Companies

Renaissance Lakewood

Headquarters
LTS Lohmann Therapie-Systeme AG
Lohmannstraße 2
D-56626 Andernach
Germany

Phone / Contact

T: +49 2632 99 0
F: +49 2632 99 2200
E: [email protected]

Connect

LTS creates innovative drug delivery solutions across transdermal. oral, wearable injection and nasal delivery routes, delivering high-quality products to global markets with an exceptional track record in commercial manufacturing. It is a global CDMO offering end-to-end development and manufacturing services for pharmaceutical and biotech companies.

LTS’s technology portfolio spans transdermal patches, oral thin films, nasal and sterile drug delivery products, wearable drug delivery devices as well as microneedle array patches. The company has more than 40 commercial products and 50+ active development programmes for small molecules, biologics, and vaccines.

Founded in 1984, LTS Lohman Therapie-System AG is a non-listed public limited company, with three locations in the US: West Caldwell, NJ, St Paul, MN, and Lakewood, NJ; a site in Netanya, Israel, and representation in Shanghai, China, in addition to its German headquarters. It employs more than >2,200 people and has a turnover of >€600 million (£525 million).

In November 2025, LTS completed its acquisition of Renaissance Lakewood.

Articles by LTS

ADVANCING CANCER CARE THROUGH ON-BODY SUBCUTANEOUS INJECTIONS: THE ONCOLOGY COMMUNITY’S PERSPECTIVE

Dr Greg Moakes discusses the role that on-body delivery systems have to play in modernising the delivery of oncology drugs, digging into the survey results of over 200 attendees of the American Society of Clinical Oncology 2025 Global Meeting as to their opinions on the place of this pivotal technology in oncological practice.

Mary Lou Glotzbach

THE POWER OF PARTNERSHIP AND CLOSE COLLABORATION FOR FILLING ON-BODY INJECTORS

Mary Lou Glotzbach and Dr Greg Moakes consider the implications of the increasing demand for high-volume injections across the drug delivery industry, and how technologies such as wearable injectors are creating novel challenges for the fill-finish process due to the novel containers involved, making the case that it is only through clear communication and close collaboration between partners that these challenges can be met and surmounted.

TRUST THE PROGRESS: INTRODUCING AUTOMATION TO ENHANCE ON-BODY INJECTOR MANUFACTURING

Greg Moakes and Tzach Sadi the process and benefits of automating the production process for its on-body injector device, Sorrel™.

Dr Iris Schnitzler

EXTENDING PATIENT-FRIENDLY DRUG DELIVERY TO HIGH-VOLUME WEARABLE DEVICES

Iris Schnitzler discusses the benefits of on-body delivery systems, including the flexibility and convenience they bring to patients managing chronic conditions, and how the Sorrel platform overcomes some of the inherent complexities and challenges of developing such a device. Dr Schnitzler then goes on to speak with Bas van Buijtenen and Andrei Yosef about the Sorrel platform and how its integration within LTS supports the company’s fundamental objectives of enabling partners and empowering patients.

LOW-COMPLEXITY, EASY-TO-USE WEARABLE INJECTION PLATFORM

Jesper Roested discusses the increasing prevalence of biologics formulated for large-volume injections in drug development and how wearable devices, including Subcuject’s offering, may be a better solution for delivering these drugs than scaled-up conventional autoinjectors.

Dr Sebastian Braun

WHY THE CONSISTENT CHALLENGES SURROUNDING MAPS ARE DISSOLVING FAST

Sebastian Braun discusses the current state of microneedle-based transdermal drug delivery, covering available microneedle delivery methods, the US FDA’s current stance on microneedle technologies and LTS’s microarray patch (MAP) system and the possibilities it represents.

QUALITY BY DESIGN IN TDS DEVELOPMENT: BENEFIT OR BUREAUCRATIC BURDEN?

Petra Botzem and Thomas Hille discuss the Quality-by-Design approach to the development of transdermal drug delivery systems as laid out in ICH guideline Q8.

ORAL THIN FILMS – REALMS OF POSSIBILITY?

Rick Chan, PhD, Executive Scientific Officer, LTS Lohmann Therapy Systems, discusses the fundamentals of transmucosal absorption and how formulation effort and the drug properties influence drug absorption in the buccal cavity.

Top